Back to Search

A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

  • Protocol Number: 202111059
  • Principal Investigator: Van Tine, Brian
  • Cancer Types: Sarcoma

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions